Mississippi Division of Medicaid Universal Preferred Drug List

Home , Tolnaftate

MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

‘Smart PA’ is Xerox’s proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not have electronic PA functionality. However, they must adhere to Medicaid’s PA criteria THERAPEUTIC PREFERRED AGENTS NON-PREFERRED AGENTS PA CRITERIA DRUG CLASS ACNE AGENTS ANTI-INFECTIVE clindamycin (gel, lotion, solution) ACZONE (dapsone) Maximum Age Limit erythromycin AKNE-MYCIN (erythromycin)  21 years – all agents AZELEX (azelaic acid) CLEOCIN-T (clindamycin) CLINDAGEL (clindamycin) clindamycin foam ERY (erythromycin) ERYGEL (erythromycin) EVOCLIN (clindamycin) FINACEA (azelaic acid) KLARON (sulfacetamide) sulfacetamide RETINOIDS RETIN-A (tretinoin) adapalene tretinoin cream AVITA (tretinoin) ATRALIN (tretinoin) DIFFERIN (adapalene) FABIOR (tazarotene) RETIN-A MICRO (tretinoin) TAZORAC (tazarotene) tretinoin gel tretinoin micro COMBINATION DRUGS/OTHERS EPIDUO (adapalene/benzoyl peroxide) ACANYA (benzoyl peroxide/clindamycin) erythromycin/benzoyl peroxide BENZACLIN GEL (benzoyl peroxide/clindamycin) sodium sulfacetamide/sulfur cream/foam/gel BENZACLIN KIT (benzoyl peroxide/ clindamycin) BENZAMYCIN PAK (benzoyl peroxide/ erythromycin) benzoyl peroxide/clindamycin 1 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

2 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

‘Smart PA’ is Xerox’s proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not have electronic PA functionality. However, they must adhere to Medicaid’s PA criteria THERAPEUTIC PREFERRED AGENTS NON-PREFERRED AGENTS PA CRITERIA DRUG CLASS ALZHEIMER’S AGENTS SmartPA CHOLINESTERASE INHIBITORS donepezil (Tablets and ODT) 5mg, 10mg ARICEPT (donepezil) All Agents EXELON PATCHES (rivastigmine) ARICEPT 23 MG (donepezil)  Documented diagnosis for both galantamine ARICEPT ODT (donepezil) preferred and non-preferred rivastigmine capsules donepezil 23mg Non Preferred Criteria EXELON Capsules (rivastigmine)  Have tried 2 different preferred agents EXELON Solution (rivastigmine) in the past 6 months galantamine ER RAZADYNE (galantamine) RAZADYNE ER (galantamine) rivastigmine patches NMDA RECEPTOR ANTAGONIST NAMENDA TABS (memantine) memantine NAMENDA SOLUTION(memantine) NAMENDA XR (memantine) COMBINATION AGENTS NAMZARIC (memantine/donepezil) Namzaric  Documented diagnosis AND  30 days of concurrent therapy with donepezil + memantine ANALGESICS, NARCOTIC - SHORT ACTING acetaminophen/codeine ABSTRAL (fentanyl) Quantity Limits codeine ACTIQ (fentanyl) Applicable quantity limit in 31 rolling dihydrocodeine/ APAP/caffeine butalbital/APAP/caffeine/codeine days. hydrocodone/APAP butalbital/ASA/caffeine/codeine  62 tablets – codeine, oxycodone/ibuprofen, meperidine, hydromorphone butorphanol tartrate (nasal) hydromorphone, fentanyl, IBUDONE (hydrocodone/ibuprofen) DEMEROL (meperidine) bultalbital/codeine combinations, meperidine DILAUDID (hydromorphone) morphine, tapentadol, dihydrocodeine morphine fentanyl combinations, tramadol, pentazocine 3 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

oxycodone/ibuprofen FIORINAL W/ CODEINE  124 tablets – butalbital/APAP 750 pentazocine/APAP (butalbital/ASA/caffeine/codeine)  145 tablets – butalbital/APAP 650 tramadol hydrocodone/ibuprofen  186 tablets – butalbital/APAP 325, butalbital/ASA 325 tramadol/APAP levorphanol LORCET (hydrocodone/APAP)  5mL (2 x 2.5 bottles) – butorphanol LORTAB (hydrocodone/APAP) nasal MAGNACET (oxycodone/APAP)  180 mL CUMULATIVE – oxycodone NORCO (hydrocodone/APAP) liquids NUCYNTA (tapentadol)  480 mL CUMULATIVE – ONSOLIS (fentanyl) hydrocodone liquids OPANA (oxymorphone) OXECTA (oxycodone) pentazocine/naloxone PERCOCET (oxycodone/APAP) PERCODAN (oxycodone/ASA) REPREXAINE (hydrocodone/ibuprofen) ROXICET (oxycodone/acetaminophen) RYBIX (tramadol) SUBSYS (fentanyl) SYNALGOS-DC (dihydrocodeine/ aspirin/caffeine) TYLENOL W/CODEINE (APAP/codeine) TYLOX (oxycodone/APAP) ULTRACET (tramadol/APAP) ULTRAM (tramadol) VICODIN (hydrocodone/APAP) VICOPROFEN (hydrocodone/ibuprofen) XODOL (hydrocodone/acetaminophen) ZAMICET (hydrocodone/APAP) ZOLVIT (hydrocodone/APAP) ZYDONE (hydrocodone/acetaminophen) 4 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

EMBEDA (morphine/naltrexone) CONZIP ER (tramadol)  18 years – Xartemis XR, Zohydro ER fentanyl patches DOLOPHINE (methadone) morphine ER tablets DURAGESIC (fentanyl) Quantity Limits Applicable quantity limit per rolling days EXALGO (hydromorphone) hydromorphone ER  31 tablets/31 days - Conzip ER, HYSINGLA ER (hydrocodone) Exalgo ER, Hysingla ER, Ryzolt , Ultram ER KADIAN (morphine)  62 tablets/31 days – Embeda, Methadone* Kadian, Methadone, Morphine ER, MS CONTIN (morphine) Opana ER, oxycodone ER, morphine ER capsules Oxycontin, Zohydro ER NUCYNTA ER (tapentadol)  10 patches/31 days – Duragesic OPANA ER (oxymorphone)*  4 patches/31 days – Butrans oxycodone ER  40 tablets/10 days – Xartemis XR OXYCONTIN (oxycodone) oxymorphone ER Non-Preferred Criteria RYZOLT (tramadol)  Have tried 2 different preferred agents tramadol ER in the past 6 months OR ULTRAM ER (tramadol)  Documented diagnosis of cancer OR Antineoplastic therapy AND 90 XARTEMIS XR (oxycodone/APAP) consecutive days on the requested ZOHYDRO ER (hydrocodone bitartrate) agent in the past 105 days

Hysingla ER - MANUAL PA  Documented diagnosis of cancer  Have tried 2 different preferred agents in the past 12 months AND  Have tried 2 different non-preferred agents in the past 12 months

OxyContin  Documented diagnosis of cancer OR 5 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Xartemis XR – MANUAL PA  Have tried 2 different preferred agents in the past 30 days  Maximum duration of therapy = 20 days per calendar year

Zohydro ER - MANUAL PA  Documented diagnosis of cancer  Have tried 3 different preferred agents in the past 12 months AND  Have tried 2 different non-preferred agents in the past 12 months

ANALGESICS/ANAESTHETICS (Topical)

VOLTAREN Gel (diclofenac sodium) SmartPA capsaicin Non Preferred Criteria diclofenac sodium solution  Have tried 1 preferred agent in the FLECTOR (diclofenac epolamine) SmartPA past 6 months LIDAMANTLE HC (lidocaine/hydrocortisone) lidocaine o Lidoderm lidocaine/prilocaine  Documented diagnosis of Herpetic LIDODERM (lidocaine) SmartPA Neuralgia OR SmartPA  Documented diagnosis of Diabetic PENNSAID Solution (diclofenac sodium ) Neuropathy xylocaine SYNERA (lidocaine/tetracaine) ZOSTRIX (capsaicin)

6 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

ANGIOTENSIN MODULATORS SmartPA ACE INHIBITORS benazepril ACCUPRIL (quinapril) Minimum Age Limit captopril ALTACE (ramipril)  ≤ 6 years – Epaned Smart PA will enalapril EPANED (epalapril) automatically be issued for this age LOTENSIN (benazepril) fosinopril MAVIK (trandolapril) Non Preferred Criteria lisinopril moexipril  Have tried 2 different preferred single quinapril perindopril entity agents in the past 6 months OR ramipril PRINIVIL (lisinopril)  90 consecutive days on the requested trandolapril UNIVASC (moexipril) agent in the past 105 days VASOTEC (enalapril) ZESTRIL (lisinopril) ACE INHIBITOR COMBINATIONS benazepril/HCTZ ACCURETIC (quinapril/HCTZ) Non Preferred Criteria captopril/HCTZ benazepril/amlodipine ACE Inhibitor/CCB enalapril/HCTZ LOTENSIN HCT (benazepril/HCTZ)  Have tried 2 different preferred fosinopril/HCTZ moexipril/HCTZ ACEI/CCB agents in the past 6 NR months OR lisinopril/HCTZ PRESTALIA (perindopril/amlodipine)  90 consecutive days on the requested trandolapril/verapamil LOTREL(benazepril/amlodipine) agent in the past 105 days UNIRETIC (moexipril/HCTZ) quinapril/HCTZ 7 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs) DIOVAN (valsartan) ATACAND (candesartan) Non Preferred Criteria losartan AVAPRO (irbesartan)  Have tried 2 different preferred single MICARDIS (telmisartan) BENICAR (olmesartan) entity agents in the past 6 months OR candesartan  90 consecutive days on the requested agent in the past 105 days COZAAR (losartan) EDARBI (azilsartan) eprosartan irbesartan telmisartan TEVETEN (eprosartan) valsartan

ARB COMBINATIONS DIOVAN-HCT (valsartan/HCTZ) ATACAND-HCT (candesartan/HCTZ) Non Preferred Criteria EXFORGE (valsartan/amlodipine) AVALIDE (irbesartan/HCTZ) ARB/CCB or ARB/CCB/Diuretic EXFORGE HCT (valsartan/amlodipine/HCTZ) AZOR (olmesartan/amlodipine)  Have tried 1 preferred ARB/CCB losartan/HCTZ BENICAR-HCT (olmesartan/HCTZ) agent in the past 6 months OR  90 consecutive days on the requested MICARDIS-HCT (telmisartan/HCTZ) candesartan/HCTZ agent in the past 105 days EDARBYCLOR (azilsartan/chlorthalidone) ENTRESTO (valsartan/sacubitril) ARB/Diuretic HYZAAR (losartan/HCTZ)  Have tried 2 different preferred irbesartan/HCTZ ARB/Diuretic products in the past 6 telmisartan/amlodipine months OR 8 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

DIRECT RENIN INHIBITOR COMBINATIONS AMTURNIDE (aliskiren/amlodipine/hctz) Non Preferred Criteria TEKAMLO (aliskiren/amlodipine)  Documented diagnosis of TEKTURNA-HCT (aliskiren/hctz) hypertension AND VALTURNA (aliskiren/valsartan)  Have tried 2 different preferred ACEI or ARB diuretic agents in the past 6

months OR  90 consecutive days on the requested agent in the past 105 days

9 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

ANTIBIOTICS (MISCELLANOUS) KETOLIDES KETEK (telithromycin) LINCOSAMIDE ANTIBIOTICS clindamycin capsules CLEOCIN (clindamycin) clindamycin solution CLEOCIN SOLUTION (clindamycin)

MACROLIDES

azithromycin BIAXIN (clarithromycin) clarithromycin ER BIAXIN XL (clarithromycin) clarithromycin IR E.E.S. (erythromycin ethylsuccinate) E.E.S. Suspension 400 (erythromycin E.E.S. Suspension 200 (erythromycin ethylsuccinate) ethylsuccinate) E-MYCIN (erythromycin) ERY-TAB (erythromycin) ERYC (erythromycin) ERYPED Suspension (erythromycin ethylsuccinate) ERYTHROCIN (erythromycin stearate) erythromycin erythromycin estolate PCE (erythromycin) ZITHROMAX (azithromycin) ZMAX (azithromycin) 10 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

‘Smart PA’ is Xerox’s proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not have electronic PA functionality. However, they must adhere to Medicaid’s PA criteria THERAPEUTIC PREFERRED AGENTS NON-PREFERRED AGENTS PA CRITERIA DRUG CLASS NITROFURAN DERIVATIVES nitrofurantoin FURADANTIN (nitrofurantoin) nitrofurantoin monohydrate macrocyrstals MACROBID (nitrofurantoin monohydrate macrocyrstals) MACRODANTIN (nitrofurantoin) Oxazolidinones SIVEXTRO (tedizolid) Sivextro, Zyvox - MANUAL PA ZYVOX (linezolid) Quantity Limit  6 tablets/month - Sivextro ANTIBIOTICS (Topical) bacitracin ALTABAX (retapamulin) bacitracin/polymixin BACTROBAN OINTMENT (mupirocin) BACTROBAN cream (mupirocin) CORTISPORIN (bacitracin/neomycin/ gentamicin sulfate polymyxin/HC) mupirocin ointment mupirocin cream ANTIBIOTICS (VAGINAL) CLEOCIN OVULES (clindamycin) AVC (sulfanilamide) CLINDESSE (clindamycin) CLEOCIN CREAM (clindamycin) METROGEL (metronidazole) clindamycin VANDAZOLE (metronidazole) metronidazole vaginal NUVESSA (metronidazole) ANTICOAGULANTS SmartPA ORAL COUMADIN (warfarin) ELIQUIS (apixaban) DVT Prophylaxis - following hip or warfarin PRADAXA (dabigatran) knee replacement XARELTO 10mg (rivaroxaban) Clinical Edit SAVAYSA (edoxaban tosylate) XARELTO 10MG & ELIQUIS  70 total days of therapy per calendar XARELTO 15 & 20mg (rivaroxaban) year  Documented diagnosis of knee 11 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

DVT and PE Treatment ELIQUIS, PRADAXA, SAVAYSA, XARELTO 15 & 20MG  Documented diagnosis of DVT or PE

Nonvalvular Atrial Fibrillation ELIQUIS, PRADAXA, SAVAYSA, XARELTO 15 & 20MG  Documented diagnosis of atrial fibrillation AND  NO contraindication of cardiac valve disease AND  60 days prior therapy with warfarin in the past 6 months OR  1 claim with the requested agent in the past 90 days

LOW MOLECULAR WEIGHT HEPARIN (LMWH)

LOVENOX (enoxaparin) Prefilled Syringe ARIXTRA (fondaparinux) LMWH – All Agents

enoxaparin  LMWH therapy in the past 3months

FRAGMIN (dalteparin) AND

fondaparinux o Documented diagnosis of cancer OR o Pregnant female OR  NO LMWH therapy in the past 3months AND 12 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

LMWH Non Preferred Criteria  Have tried 1 different preferred agent in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days

ANTICONVULSANTS SmartPA ADJUVANTS carbamazepine APTIOM (eslicarbazepine) Minimum Age Limit CARBATROL (carbamazepine) BANZEL (rufinamide)  1 year - Banzel DEPAKOTE ER (divalproex) carbamazepine XR  2 years – Onfi DEPAKOTE SPRINKLE (divalproex) DEPAKENE (valproic acid) Quantity Limit divalproex DEPAKOTE (divalproex)  3 Twin Packs/31 days - Diastat divalproex ER EQUETRO (carbamazepine)

FANATREX SUSPENSION (gabapentin)NR EPITOL (carbamazepine) Topiramate ER – Step Edit felbamate FYCOMPA (perampanel)  90 consecutive days on the requested gabapentin FELBATOL (felbamate) agent in the past 105 days AND GABITRIL (tiagabine) GRALISE (gabapentin) documented diagnosis of seizure OR lamotrigine HORIZANT (gabapentin)  30 day trial with topiramate IR in the levetiracetam LAMICTAL XR (lamotrigine)* past 6 months oxcarbazepine KEPPRA (levetiracetam) oxcarbazepine suspension KEPPRA XR (levetiracetam) 13 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

SUCCINIMIDES ethosuximide CELONTIN (methsuximide) ZARONTIN (ethosuximide)

14 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

‘Smart PA’ is Xerox’s proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not have electronic PA functionality. However, they must adhere to Medicaid’s PA criteria THERAPEUTIC PREFERRED AGENTS NON-PREFERRED AGENTS PA CRITERIA DRUG CLASS ANTIDEPRESSANTS, OTHER SmartPA bupropion APLENZIN (bupropion HBr) Minimum Age Limit bupropion SR desvenlafaxine  18 years - all drugs bupropion XL DESYREL (trazodone) BRINTELLIX (vortioxetine) EFFEXOR (venlafaxine) Non Preferred Criteria  Have tried 2 different preferred mirtazapine EFFEXOR XR (venlafaxine) ‘Antidepressants, Other’ Class in the trazodone EMSAM (selegiline transdermal) past 6 months OR venlafaxine FETZIMA ER (levomilnacipran)  Have tried BOTH a preferred venlafaxine ER tablets FORFIVO XL (bupropion) ‘Antidepressant, SSRI’ and VIIBRYD (vilazodone) IRENKA (duloxetine) ‘Antidepressants, Other’ in the past 6 KHEDEZLA ER (desvenlafaxine) months OR MARPLAN (isocarboxazid)  90 consecutive days on the requested NARDIL (phenelzine) agent in the past 105 days nefazodone OLEPTRO ER (trazodone) Irenka Anxiety PRISTIQ (desvenlafaxine)  Documented diagnosis AND REMERON (mirtazapine)  Have tried 2 of the following preferred Tranylcypromine agents: Effexor, Effexor XR, Paxil, or venlafaxine ER capsules Zoloft in the past 6 months OR venlafaxine XR  90 consecutive days on the requested WELLBUTRIN (bupropion) agent in the past 105 days WELLBUTRIN SR WELLBUTRIN XL (bupropion HCl) Depression  Documented diagnosis AND  Have tried 2 different preferred ‘Antidepressants, Other’ Class in the past 6 months OR  Have tried BOTH a preferred ‘Antidepressant, SSRI’ and ‘Antidepressants, Other’ Class in the past 6 months OR  90 consecutive days on the requested 15 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Diabetic Peripheral Neuropathy  Documented diagnosis AND  Have tried Lyrica in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days

Cymbalta (see Fibromyalgia Agents)

ANTIDEPRESSANTS, SSRIs SmartPA citalopram CELEXA (citalopram) Minimum Age Limits escitalopram fluoxetine DR  6 years - Zoloft fluoxetine fluvoxamine ER*  7 years – Prozac fluvoxamine LEXAPRO (escitalopram)  8 years - Luvox paroxetine CR LUVOX (fluvoxamine)  9 years - Celexa paroxetine IR LUVOX CR (fluvoxamine)  12 years - Lexapro sertraline paroxetine suspension  18 years - Luvox CR, Paxil, Prozac PAXIL CR (paroxetine) 90 mg PAXIL SUPENSION PAXIL Tablets (paroxetine) Non Preferred Criteria PEXEVA (paroxetine)  Have tried 2 different preferred agents PROZAC (fluoxetine) in the past 6 months OR SARAFEM (fluoxetine)  90 consecutive days on the requested ZOLOFT (sertraline) agent in the past 105 days ANTIEMETICS SmartPA 5HT3 RECEPTOR BLOCKERS ondansetron ANZEMET (dolasetron) Quantity Limits ondansetron solution granisetron  4 tablets/31 days - Varubi ondansetron ODT  6 tablets/31 days – Akynzeo SANCUSO (granisetron)  30 tablets/31 days – Zofran 16 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Non Preferred Agents  Have tried 1 preferred agent in the past 6 months

Injectables in this class closed to point of sale. PA required if not administered in clinic/hospital. ANTIEMETIC COMBINATIONS AKYNZEO (netupitant/palonosetron) Akynzeo - MANUAL PA DICLEGIS (doxylamine/pyridoxine)  Documented diagnosis of cancer OR Antineoplastic history AND  Chemotherapy regimen includes use of a highly or moderately emetogenic chemotherapeutic agent AND  History of prior use of preferred combination antiemetic therapy AND  Concurrent use of dexamethasone per PI CANNABINOIDS CESAMET (nabilone) MARINOL (dronabinol) dronabinol

17 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

voriconazole ^ Cresemba - MANUAL PA  Minimum age limit > 18 years AND  Documented diagnosis of invasive

18 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Sporanox  HIV opportunistic infection criteria OR  Documented diagnosis of a transplant OR  History of an immunosuppressant in the past 6 months OR  Have tried 2 different preferred agents in the past 6 months ANTIFUNGALS (Topical) SmartPA ANTIFUNGALS ciclopirox cream/gel/solution/suspension BENSAL HP (benzoic acid/salicylic acid) Non Preferred Criteria clotrimazole CICLODAN KIT  Have tried 2 different preferred agents econazole ciclopirox kit/shampoo in the past 6 months ketoconazole cream CNL 8 (ciclopirox) ketoconazole shampoo ERTACZO (sertaconazole) miconazole OTC EXELDERM (sulconazole) nystatin EXTINA (ketoconazole) terbinafine OTC cream,gel,spray JUBLIA (efinaconazole)NR tolnaftate OTC KERYDIN (tavaborole) ketoconazole foam LAMISIL (terbinafine) solution LOPROX (ciclopirox) LUZU (luliconazole) MENTAX (butenafine) NAFTIN (naftifine) NIZORAL (ketoconazole) 19 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

20 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Non Preferred Criteria – ORAL & NASAL  Have tried 1 preferred agent in the past 90 days

NASAL IMITREX (sumatriptan) sumatriptan Quantity Limit - NASAL ZOMIG (zolmitriptan)  1 box/31 days

21 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Zecuity  Have tried 2 preferred agents (oral, nasal, or injectable) in the past 90 days

ANTINEOPLASTICS – SELECTED SYSTEMIC ENZYME INHIBITORS AFINITOR (everolimus) FARYDAK (panobinostat) Farydak - MANUAL PA BOSULIF (bosutinib) GLEOSTINE (lomustine)  Documented diagnosis of multiple SmartPA CAPRELSA (vandetanib) IBRANCE (palbociclib) myeloma AND COMETRIQ (cabozantinib) SmartPA LENVIMA (lenvatinib)  Used in combination with bortezomib GILOTRIF (afatanib) LYNPARZA (olaparib) SmartPA GLEEVEC (imatinib mesylate) and dexamethasone per PI AND ICLUSIG (ponatinib)  History of 2 prior regimens including IMBRUVICA (ibrutnib) bortezomib and an INLYTA (axitinib) immunomodulatory agent IRESSA (gefitinib) JAKAFI (ruxolitinib) Ibrance MEKINIST (trametinib dimethyl sulfoxide)  Documented diagnosis of breast NEXAVAR (sorafenib) cancer AND SPRYCEL (dasatinib)  Concurrent therapy with letrozole STIVARGA (regorafenib)

SUTENT (sunitinib) Lenvima TAFINLAR (dabrafenib)  Documented diagnosis of thyroid TARCEVA (erlotinib) cancer TASIGNA (nilotinib)

TYKERB (lapatinib ditosylate) 22 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

ANTIPARASITICS (Topical) SmartPA PEDICULICIDES permethrin 1% lindane Minimum Age/Weight Limit for NATROBA (spinosad) Step Edit malathion Pediculicides OVIDE (malathion)  50 kg - lindane shampoo SKLICE (ivermectin)  2 months – permethrin 1%(OTC) ULESFIA (benzyl alcohol)  6 months – Natroba, SKLICE, Ulesfia  2 years – piperonyl/pyrethrins (OTC)

 6 years – Ovide

Natroba – Step Edit  History of permethrin 1% topical lotion OR piperonyl/pyrethrin in the past 90 days

Non Preferred Criteria  History of permethrin 1% topical lotion OR piperonyl/pyrethrin in the past 90 days AND  History of Natroba in the past 90 days

Ulesfia Ulesfia is no longer covered due to no longer being rebated.

23 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Non Preferred Criteria  History of permethrin 5% in the past 90 days

ANTIPARKINSON’S AGENTS (Oral) SmartPA ANTICHOLINERGICS benztropine COGENTIN (benztropine) Non Preferred Criteria trihexyphenidyl  Documented diagnosis of Parkinson’s disease AND  Have tried 2 different preferred agents in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days

COMT INHIBITORS COMTAN (entacapone) TASMAR (tolcapone) tolcapone

DOPAMINE AGONISTS ropinirole MIRAPEX (pramipexole) MIRAPEX ER (pramipexole) NEUPRO (rotigotine)

24 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

MAO-B INHIBITORS selegiline AZILECT (rasagiline) ELDEPRYL (selegiline) ZELAPAR (selegiline) OTHERS amantadine levodopa/carbidopa ODT Lodosyn bromocriptine levodopa/carbidopa/entacapone  Documented diagnosis of Parkinson’s levodopa/carbidopa LODOSYN (carbidopa) disease AND PARCOPA (levodopa/carbidopa)  History of a carbidopa/levodopa PARLODEL (bromocriptine) combination product in the past 45 RYTARY ER (levodopa/carbidopa) days SINEMET (levodopa/carbidopa) SINEMET CR (levodopa/carbidopa) STALEVO (levodopa/carbidopa/entacapone)

ANTIPSYCHOTICS SmartPA ORAL

ABILIFY (aripiprazole) SmartPA aripiprazole Minimum Age Limits SmartPA amitriptyline/perphenazine CLOZARIL (clozapine)  3 years - Haldol

chlorpromazine FANAPT (iloperidone)* SmartPA  5 years – Risperdal SmartPA clozapine FAZACLO (clozapine) SmartPA  6 years – Abilify SmartPA  10 years – Saphris, Seroquel, fluphenazine GEODON (ziprasidone) SmartPA Symbyax haloperidol SmartPA HALDOL (haloperidol)  13 years – Zyprexa SmartPA SmartPA olanzapine INVEGA (paliperidone)  18 years – Clozaril, Fanapt, Geodon, perphenazine Invega, Latuda, Rexulti 25 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

risperidone SmartPA LATUDA (lurasidone)SmartPA SEROQUEL (quetiapine) SmartPA NAVANE (thiothixene) Concurrent Therapy Limits – All SmartPA Agents SEROQUEL XR (quetiapine) SmartPA olanzapine/fluoxetine  Limited to 2 products concurrently thioridazine paliperidone SmartPA  60 days with > 3 atypical thiothixene quetiapine antipsychotics in the last 90 days will trifluoperazine REXULTI (brexpiprazole) require a manual PA SmartPA SmartPA ziprasidone RISPERDAL (risperidone) Abilify Tablets (excluding ODT) SmartPA SAPHRIS (asenapine)*  Detailed Abilify Tablet Splitting found

SYMBYAX (olanzapine/fluoxetine) SmartPA here: VERSACLOZ (clozapine)NR  Use ½ tablet of the higher strength.

ZYPREXA (olanzapine) SmartPA  1 tablet splitter/ year

Non Preferred Criteria  Have tried 2 preferred atypical antipsychotic agents in the past 12 months OR  30 consecutive days on the requested agent in the past 180 days

Latuda  Females of childbearing age o > 18 years will approve automatically o < 18 years will need an age waiver by manual PA OR  Males see Non Preferred Criteria noted above SmartPA INJECTABLE, ATYPICALS ABILIFY (aripiprazole) Effective 11-1-2012, injectable ARISTADA ER (aripiprazole lauroxil)NR antipsychotics are closed to POS GEODON (ziprasidone) except for Long Term Care (LTC) beneficiaries. INVEGA SUSTENNA (paliperidone palmitate)

26 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Invega Trinza  Minimum Age AND  Documented diagnosis AND  History of 4 claims of Invega Sustenna in the past 180 days

SmartPA ANTIRETROVIRALS INTEGRASE STRAND TRANSFER INHIBITORS ISENTRESS (raltegravir potassium) VITEKTA (elvitegravir) Non Preferred Criteria TIVICAY (dolutegravir sodium)  1 claim with the requested agent in the past 105 days NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) abacavir sulfate RETROVIR (zidovudine) didanosine DR capsule VIDEX EC (didanosine) EMTRIVA (emtricitabine) EPIVIR (butransine) lamivudine ZERIT (stavudine) stavudine VIDEX SOLUTION (didanosine) VIREAD (tenofovir disoproxil fumarate) ZIAGEN (abacavir sulfate) zidovudine 27 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

PROTEASE INHIBITORS (NON-PEPTIDIC) PREZISTA (darunavir ethanolate) APTIVUS (tipranavir) PREZCOBIX (darunavir/cobicistat) ENTRY INHIBITORS – CCR5 CO-RECEPTOR ANTAGONISTS SELZENTRY (maraviroc)

ENTRY INHIBITORS – FUSION INHIBITORS FUZEON (enfuvirtide) COMBINATION PRODUCTS - NRTIs abacavir/lamivudine/zidovudine COMBIVIR (lamivudine/zidovudine) EPZICOM (abacavir/lamivudine) lamivudine/zidovudine TRIZIVIR (abacavir/lamivudine/zidovudine) COMBINATION PRODUCTS – NUCLEOSIDE & NUCLEOTIDE ANALOG RTIs TRUVADA (emtricitabine/tenofovir)

28 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Triumeq – MANUAL PA  Medical reasoning beyond convenience or enhanced compliance over the preferred agents (Epzicom + Tivicay) COMBINATION PRODUCTS – NUCLEOSIDE & NUCLEOTIDE ANALOGS & NON-NUCLEOSIDE RTIs ATRIPLA (efavirenz/emtricitabine/tenofovir) COMPLERA (emtricitabine/rilpivirine/tenofovir) COMBINATION PRODUCTS – PROTEASE INHIBITORS KALETRA (lopinavir/ritonavir)

ANTIVIRALS (Oral) – ANTIHERPETIC AGENTS acyclovir famciclovir valacyclovir FAMVIR (famciclovir) SITAVIG (acyclovir) VALTREX (valacyclovir) ZOVIRAX (acyclovir)

29 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

ATOPIC DERMATITIS SmartPA ELIDEL (pimecrolimus) PROTOPIC (tacrolimus) Minimum Age Limit tacrolimus  2 years – Elidel, Protopic 0.03%  6 years – Protopic 0.1%

Non Preferred Criteria  Have tried 1 preferred agent in the past 6 months

30 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

31 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

BLADDER RELAXANT PREPARATIONS SmartPA oxybutynin ER, IR DETROL (tolterodine) Non Preferred Criteria VESICARE (solifenacin) DETROL LA (tolterodine)  Have tried 2 different preferred agents DITROPAN XL (oxybutynin) in the past 6 months ENABLEX (darifenacin) GELNIQUE (oxybutynin) MYRBETRIQ (mirabegron) OXYTROL (oxybutynin) SANCTURA (trospium) SANCTURA XR (trospium) tolterodine tolterodine ER TOVIAZ (fesoterodine fumarate) trospium 32 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

BPH AGENTS SmartPA ALPHA BLOCKERS doxazosin alfuzosin Female tamsulosin CARDURA (doxazosin)  Cardura, Flomax, Proscar, terazosin, terazosin CARDURA XL (doxazosin) or Uroxatral AND a documented dutasteride/tamsulosin diagnosis based on a state accepted diagnosis FLOMAX (tamsulosin)

JALYN (dutasteride/tamsulosin) Non Preferred Criteria - MALE RAPAFLO (silodosin)  Have tried 2 different preferred agents UROXATRAL (alfuzosin) in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days

33 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

CIALIS (tadalafil) Cialis – MANUAL PA  Male gender AND  Documented diagnosis for Benign Prostatic Hypertrophy AND  NO history of Erectile Dysfunction AND  Signed waiver stating treatment is NOT for Erectile Dysfunction AND  Have tried 2 different preferred agents in the past 6 months

BRONCHODILATORS & COPD AGENTS ANTICHOLINERGICS & COPD AGENTS ATROVENT HFA (ipratropium) DALIRESP (roflumilast) ipratropium INCRUSE ELLIPTA (umeclidinium) SPIRIVA HANDIHALER (tiotropium) SPIRIVA RESPIMAT (tiotropium) TUDORZA PRESSAIR (aclidinium)

ANTICHOLINERGIC-BETA AGONIST COMBINATIONS albuterol/ipratropium ANORO ELLIPTA (umeclidinium/vilanterol) COMBIVENT RESPIMAT (albuterol/ipratropium) STIOLTO RESPIMAT (tiotropium/olodaterol)

34 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

SmartPA INHALERS, LONG ACTING FORADIL (formoterol) ARCAPTA (indacaterol) Minimum Age Limit SEREVENT (salmeterol) STRIVERDI RESPIMAT (olodaterol)  4 years – Serevent  5 years – Foradil  18 years – Arcapta, Striverdi Respimat

Non Preferred Criteria  Have tried 1 preferred agent in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days

Arcapta & Striverdi Respimat  Documented diagnosis of COPD AND  Have tried 1 preferred agent in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days

35 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Xopenex  1 claim for a albuterol in the past 30 days ORAL albuterol VOSPIRE ER (albuterol) metaproterenol terbutaline

CALCIUM CHANNEL BLOCKERS SmartPA SHORT-ACTING diltiazem CALAN (verapamil) Quantity Limit - nimodipine nicardipine CARDIZEM (diltiazem)  252 tablets/ 21 days nifedipine isradipine  2520 mL/21 days verapamil nimodipine PROCARDIA (nifedipine) Non Preferred Criteria  Have tried 2 different preferred Short Acting CCB agents in the past 6 months OR  90 consecutive days on the requested 36 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

nimodipine  Documented diagnosis of subarachnoid hemorrhage in the past 45 days AND  Duration of therapy = 21 days

LONG-ACTING amlodipine ADALAT CC (nifedipine) Non Preferred Criteria diltiazem ER CALAN SR (verapamil)  Have tried 2 different preferred Long felodipine ER CARDENE SR (nicardipine) Acting CCB agents in the past 6 nifedipine ER CARDIZEM CD (diltiazem) months OR  90 consecutive days on the requested verapamil ER CARDIZEM LA (diltiazem) DILACOR XR (diltiazem) agent in the past 105 days nisoldipine NORVASC (amlodipine) PROCARDIA XL (nifedipine) SULAR (nisoldipine) TIAZAC (diltiazem) verapamil ER PM VERELAN/VERELAN PM (verapamil)

CALORIC AGENTS BOOST (includes all Boost) COMPLEAT Non Preferred Agents - MANUAL PA BRIGHT BEGINNINGS EO28 SPLASH CARNATION INSTANT BREAKFAST FIBERSOURCE DUOCAL ISOSOURCE ENSURE JEVITY JUVEN KINDERCAL GLUCERNA PEPTAMEN 37 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

SmartPA CEPHALOSPORINS – First Generation cefadroxil cephalexin tablets Non Preferred Criteria – all cephalexin capsules KEFLEX (cephalexin) generations  Have tried 2 different preferred agents in the past 6 months

SmartPA CEPHALOSPORINS – Second Generation cefaclor capsules cefaclor ER cefprozil cefaclor suspension cefuroxime tablets cefuroxime suspension CEFTIN (cefuroxime)

38 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

TOBI PODHALER (tobramycin)  12 years - Orkambi tobramycin All Agents  Documented diagnosis Cystic Fibrosis

Kalydeco  Requires 1 claim with Kalydeco in the past 105 days OR  NEW STARTS – MANUAL PA o Diagnosis of cystic fibrosis with a G551D,G1244E, G1349D,

39 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Orkambi – MANUAL PA

TOBI Podhaler – MANUAL PA  Therapy with a preferred tobramycin nebulizer solution in the past 90 days AND  Documented significant impairment with valid clinical reasoning the preferred agent cannot be used

CYTOKINE & CAM ANTAGONISTS COSENTYX (secukinumab) SmartPA ACTEMRA (tocilizumab)NR Orencia, Remicade and Stelara are for ENBREL (etanercept) CIMZIA (certolizumab) administration in hospital or clinic setting. PA will not be issued at Point HUMIRA (adalimumab) ENTYVIO (vedolizumab) of Sale without justification. ILARIS (canakinumab) methotrexate KINERET (anakinra) Cosentyx ORENCIA (abatacept)  > 18 years = Minimum Age OTEZLA (apremilast)  Documented diagnosis of plaque OTREXUP (methotrexate) psoriasis in the past 2 years AND RASUVO (methotrexate)  90 consecutive days of Humira in the REMICADE (infliximab) past year 40 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

ERYTHROPOIESIS STIMULATING PROTEINS SmartPA ARANESP (darbepoetin) MIRCERA (methoxy polyethylene glycol-epoetin- Mircera EPOGEN (rHuEPO) beta)  Documented diagnosis chronic renal PROCRIT (rHuEPO) failure in the past 2 years AND  Trial of a preferred agent in the past 6 months OR  1 claim for the requested agent in past 105 days

FIBROMYALGIA AGENTS LYRICA (pregabalin) CYMBALTA (duloxetine) SmartPA Cymbalta SAVELLA (milnacipran) duloxetine Minimum Age Limit  18 years

Fibromyalgia  Documented diagnosis AND  Have tried BOTH Lyrica and Savella in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days

Anxiety  Documented diagnosis AND  Have tried 2 of the following preferred agents: Effexor, Effexor XR, Paxil, or Zoloft in the past 6 months OR 41 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Depression  Documented diagnosis AND  Have tried 2 different preferred ‘Antidepressants, Other’ Class in the past 6 months OR  Have tried BOTH a preferred ‘Antidepressant, SSRI’ and ‘Antidepressants, Other’ Class in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days Diabetic Peripheral Neuropathy  Documented diagnosis AND  Have tried Lyrica in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days FLUOROQUINOLONES (Oral) SmartPA AVELOX (moxifloxacin) ciprofloxacin ER Non Preferred Criteria ciprofloxacin tablets CIPRO (ciprofloxacin)  1 claim for a preferred agent in past CIPRO XR (ciprofloxacin) 30 days FACTIVE (gemifloxacin) Cipro suspension age > 12 years LEVAQUIN (levofloxacin)  1 claim for a preferred agent in past levofloxacin 30 days moxifloxacin NOROXIN (norfloxacin) Cipro Suspension for age < 12 years ofloxacin  Anthrax infection or exposure OR  Cystic Fibrosis OR  Pneumonic plague OR tularemia AND history of doxycycline in the past 3 42 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Levaquin Tablets & Levaquin solution age > 12 years  1 claim for preferred agent or SMZ/TMP in past 14 days OR  1 claim for a preferred agent in past 30 days

Levaquin solution for age < 12 years  Anthrax infection or exposure OR  7 days of therapy with a preferred agent from 2 of the classes below in the past 3 months AND o Penicillin, 2nd or 3rd generation cephalosporin, or macrolide  Cipro suspension in the past 3 months GAUCHER’S DISEASE ELELYSO (taliglucerase alfa) CERDELGA (eliglustat) ZAVESCA (miglustat) CEREZYME(imiglucerase) VPRIV (velaglucerase alfa) GENITAL WARTS & ACTINIC KERATOSIS AGENTS ALDARA (imiquimod) Age Edit CARAC (fluorouracil) Minimum Age Limit CONDYLOX (podofilox)Age Edit diclofenac 3% gel  12 years – Aldara imiquimod Age Edit  18 years – Condylox, Picato, EFUDEX (fluorouracil) Veregen

43 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

NOTE: Institutional sized products are Non Preferred

GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS ADVAIR HFA (fluticasone/salmeterol) ADVAIR Diskus (fluticasone/salmeterol)* SmartPA Minimum Age Limit DULERA (mometasone/formoterol) BREO ELLIPTA (fluticasone/vilanterol)  4-11 years – Advair 100-50 Diskus - SYMBICORT (budesonide/formoterol) Smart PA will automatically be issued for this age range  > 12 years – Advair 250-50, Advair 500-50 44 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

ranitidine tablet ZANTAC (ranitidine)

PROTON PUMP INHIBITORS NEXIUM (esomeprazole) ACIPHEX SPRINKLE (rabeprazole) omeprazole Rx ACIPHEX Tablet (rabeprazole) PROTONIX PACKET (pantoprazole) DEXILANT (dexlansoprazole) lansoprazole Rx omeprazole sod. bicarb. pantoprazole PREVACID Rx (lansoprazole) PREVACID SOLU-TAB (lansoprazole) PRILOSEC RX (omeprazole) PROTONIX (pantoprazole) Rabeprazole

OTHER CARAFATE SUSPENSION (sucralfate) CARAFATE TABLET (sucralfate) misoprostol CYTOTEC (misoprostol) sucralfate tablet sucralfate suspension

GROWTH HORMONE SmartPA NORDITROPIN (somatropin) GENOTROPIN (somatropin) All Agents for Age > 18 years NUTROPIN AQ (somatropin) HUMATROPE (somatropin)  Documented diagnosis of craniopharyngioma, 45 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Non Preferred Criteria  Have tried 1 preferred agent in the past 6 months OR  84 consecutive days on the requested agent in the past 105 days H. PYLORI COMBINATION TREATMENTS PYLERA (bismuth subcitrate potassium, OMECLAMOX (omeprazole, clarithromycin, Quantity Limit metronidazole, tetracycline) amoxicillin)  1 treatment course/ year PREVPAC (lansoprazole, amoxicillin, clarithromycin)

HEPATITIS C TREATMENTS HARVONI (ledipasvir/sofosbuvir)∞ DAKLINZA (daclatasvir) ∞ ∞ Daklinza, Harvoni, Olysio, Sovaldi, PEGASYS (peginterferon alfa-2a) OLYSIO (simeprevir)∞ Technivie, Viekira – MANUAL PA PEG-INTRON (peginterferon alfa-2b) REBETOL (ribavirin) ribavirin tablets RIBAPAK DOSEPACK (ribavirin) SOVALDI (sofosbuvir)∞ ribavirin capsules TECHNIVIE (ombitasvir/paritaprevir/ritonavir) ∞ RIBASPHERE (ribavirin)

VIEKIRA (ombitasvir/paritaprevir/ritonavir)∞

HYPERURICEMIA & GOUT SmartPA allopurinol colchicine capsules Non Preferred Criteria COLCRYS (colchicine) MITIGARE (colchicines)NR  Have tried 2 different preferred agents 46 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS BYDUREON (exenatide) BYETTA (exenatide) JANUMET (sitagliptin/metformin) KAZANO (alogliptin/metformin)

JANUMET XR (sitagliptin/metformin) NESINA (alogliptin) JANUVIA (sitagliptin) OSENI (alogliptin/pioglitazone) JENTADUETO (linagliptin/metformin) SYMLIN (pramlintide) KOMBIGLYZE XR (saxagliptin/metformin) TRULICITY (dulaglutide) TANZEUM (albiglutide) VICTOZA (liraglutide) TRADJENTA (linagliptin) ONGLYZA (saxagliptin)

HYPOGLYCEMICS, INSULINS AND RELATED AGENTS SmartPA HUMALOG VIAL (insulin lispro) AFREZZA (insulin) Non Preferred Criteria HUMALOG MIX VIAL (insulin lispro/ lispro APIDRA (insulin glulisine)  Documented diagnosis of Diabetes protamine) HUMALOG KWIKPEN (insulin lispro) Mellitus AND HUMULIN VIAL (insulin) HUMALOG MIX KWIKPEN (insulin lispro/ lispro  Have tried 1 preferred product in the LANTUS SOLOSTAR & VIAL (insulin glargine) protamine) past 6 months LEVEMIR FLEXPEN & VIAL (insulin detemir) HUMULIN KWIKPEN (insulin) NOVOLOG FLEXPEN & VIAL (insulin aspart) NOVOLIN FLEXPEN (insulin) NOVOLOG MIX FLEXPEN & VIAL (insulin aspart/ NOVOLIN VIAL (insulin) aspart protamine) TOUJEO (insulin glargine) TRESIBA (insulin degludec)NR

HYPOGLYCEMICS, MEGLITINIDES repaglinide nateglinide PRANDIMET (repaglinide/metformin) 47 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS FARXIGA (dapaglifozin) INVOKANA (canagliflozin) JARDIACE (empagliflozin)NR

HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR COMBINATIONS GLYXAMBI (empagliflozin/linagliptin) INVOKAMET (canaglifozin/metformin) SYNJARDY (empagliflozin/meformin)NR XIGDUO (dapaglifozin/metformin) HYPOGLYCEMICS, TZDS THIAZOLIDINEDIONES pioglitazone ACTOS (pioglitazone) AVANDIA (rosiglitazone)

TZD COMBINATIONS ACTOPLUS MET (pioglitazone/metformin) ACTOPLUSMET XR (pioglitazone/metformin) DUETACT (pioglitazone/glimepiride) AVANDARYL (rosiglitazone/glipizide) AVANDAMET (rosiglitazone/metformin) pioglitazone/metformin

IDIOPATHIC PULMONARY FIBROSIS SmartPA 48 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

IMMNOSUPPRESSIVE (ORAL) SmartPA AZASAN (azathioprine) ASTAGRAF XL (tacrolimus)NR Minimum Age Limit azathioprine ENVARSUS XR (tacrolimus)NR  13 years - Rapamune CELLCEPT (mycophenolate) HECORIA (tacrolimus)NR  18 years - Zortress cyclosporine sirolimus Astagraf, Cellcept, Envarsus XR, cyclosporine modified Hecoria, Prograf GENGRAF (cyclosporine)  Documented diagnosis for heart mycophenolate mofetil transplant, kidney transplant, liver MYFORTIC (mycophenolic acid) transplant, or a State accepted NEORAL (cyclosporine) diagnosis PROGRAF (tacrolimus) RAPAMUNE (sirolimus) Azasan SANDIMMUNE (cyclosporine)  Documented diagnosis of kidney tacrolimus transplant, RA, or a State accepted ZORTRESS (everolimus) diagnosis

Gengraf, Neoral, Sandimmune  Documented diagnosis of heart transplant, kidney transplant, liver transplant, psoriasis, RA, or a State – accepted diagnosis OR  A MANUAL PA review for a diagnosis of Kimura’s disease or multifocal motor neuropathy

Myfortic  Documented diagnosis of kidney transplant or psoriasis 49 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Rapamune & Zortress  Documented diagnosis of kidney transplant

IMMUNE GLOBULINS CARIMUNE NF BIVIGAM FLEBOGAMMA DIF GAMMAGARD SD GAMASTAN SD GAMMAPLEX GAMMAGARD PRIVIGEN GAMMAKED GAMUNEX-C HIZENTRA HYQVIA OCTAGAM

INTRANASAL RHINITIS AGENTS ANTICHOLINERGICS ipratropium ATROVENT (ipratropium)

ANTIHISTAMINES PATANASE (olopatadine) ASTEPRO (azelastine) azelastine olopatadine

SmartPA ANTIHISTAMINE/CORTICOSTEROID COMBINATION DYMISTA (azelastine/fluticasone)

50 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

OMNARIS (ciclesonide) Rhinocort Aqua RHINOCORT AQUA (budesonide) Smart PA will be issued for pregnant triamcinolone women. VERAMYST (fluticasone)  A documented diagnosis of ZETONNA (ciclesonide) pregnancy OR a pregnancy indicator submitted on the pharmacy claim at Point of Sale

IRRITABLE BOWEL SYNDROME/SHORT BOWEL SYNDROME AGENTS/SELECTED GI AGENTS SmartPA IRRITABLE BOWL SYNDROME/SHORT BOWEL SYNDROME AGENTS dicyclomine alosetron∞ ∞ Amitiza, Fulyzaq, Gattex, Linzess, hyoscyamine AMITIZA (lubiprostone)∞ Lotronex, Relistor, or Zorbtive BENTYL (dicyclomine)  1 claim for the requested agent in the GATTEX (teduglutide) past 105 days OR LEVSIN (hyoscyamine)  MANUAL PA - All new patients LEVSIN-SL (hyoscyamine) require manual review. LINZESS (linaclotide) ∞ LOTRONEX (alosetron) ∞ NUTRESTORE POWDER PACK (glutamine) RELISTOR (methylnaltrexone)NR ZORBTIVE (somatropin) ∞ SELECTED GI AGENTS FULYZAQ (crofelemer) ∞ Movantik - MANUAL PA MOVANTIK (naloxegol)

LEUKOTRIENE MODIFIERS SmartPA 51 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

SmartPA LIPOTROPICS, OTHER (Non-statins) BILE ACID SEQUESTRANTS cholestyramine COLESTID (colestipol) All Agents, All Sub-Classes both colestipol QUESTRAN (cholestyramine) Preferred (exception is Zetia) and WELCHOL (colesevelam) Non Preferred  90 consecutive days on the requested agent in the past 105 days OR  Have tried 1 statin or statin combination agent in the past year OR  One of the following exceptions: o Welchol AND Type 2 diabetes AND 1 preferred oral antidiabetic agent in the past 180 days OR o Pregnant female OR o Documented diagnosis of liver disease OR o Documented diagnosis for hypertriglyceridemia OR o Clinical justification a statin or statin combination product cannot be used

Non Preferred Criteria  Have tried 2 different preferred Non- statin Lipotropic agents in the past 6 52 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

OMEGA-3 FATTY ACIDS LOVAZA (omega-3-acid ethyl esters) VASCEPA (icosapent ethyl) Non Preferred Criteria  Have tried 2 different preferred Non- statin Lipotropic agents in the past 6 months CHOLESTEROL ABSORPTION INHIBITORS ZETIA (ezetimibe) Zetia does not have to meet the trial of 1 statin or statin combination agent in the past year FIBRIC ACID DERIVATIVES fenofibrate nanocrystallized 145mg ANTARA (fenofibrate, micronized) Fibric Acid Derivative Non Preferred gemfibrozil fenofibrate 40mg tablet Criteria TRICOR (fenofibrate nanocrystallized) fenofibrate, micronized  Have tried 2 different fibric acid TRILIPIX (fenofibric acid) fenofibric acid derivatives in the past 6 months FENOGLIDE (fenofibrate) FIBRICOR (fenofibric acid) LIPOFEN (fenofibrate) LOFIBRA (fenofibrate) LOPID (gemfibrozil) TRIGLIDE (fenofibrate)

MTP INHIBITOR JUXTAPID (lomitapide) MANUAL PA

APOLIPOPROTEIN B-100 SYNTHESIS INHIBITOR KYNAMRO (mipomersen) MANUAL PA

53 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

LIPOTROPICS, STATINS SmartPA STATINS atorvastatin ALTOPREV (lovastatin) Simvastatin 80mg CRESTOR (rosuvastatin) fluvastatin ER  12 months of therapy with simvastatin LESCOL (fluvastatin) LIPITOR (atorvastatin) 80mg AND LESCOL XL (fluvastatin) LIVALO (pitavastatin)  NO myopathy contraindication

lovastatin MEVACOR (lovastatin) Non Preferred Criteria pravastatin PRAVACHOL (pravastatin)  Have tried 2 different preferred statin ZOCOR (simvastatin) simvastatin or statin combination agents in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days STATIN COMBINATIONS atorvastatin/amlodipine ADVICOR (lovastatin/niacin) Non Preferred Criteria SIMCOR (simvastatin/niacin) CADUET (atorvastatin/amlodipine)  Have tried 2 different preferred statin VYTORIN (simvastatin/ezetimibe) LIPTRUZET (atorvastatin/ezetimibe) or statin combination agents in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days

54 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

MISCELLANEOUS BRAND/GENERIC CLONIDINE CATAPRES-TTS (clonidine) clonidine patches clonidine tablets CATAPRES (clonidine)

EPINEPHRINE EPIPEN (epinephrine) ADRENACLICK (epinephrine) EPIPEN JR (epinephrine) AUVI-Q (epinephrine)

MISCELLANEOUS alprazolam alprazolam ERSmartPA Alprazolam ER CUMULATIVE hydroxyzine hcl syrup BUNAVAIL (buprenorphine/naloxone) quantity limit hydroxyzine pamoate buprenorphine/naloxone  31 tablets/31 days  Exception –previously stable on 2 megestrol suspension 625mg/5mL hydroxyzine hcl tablets SmartPA tablets/day in the past 90 days SUBOXONE (buprenorphine/naloxone) KORLYM (mifepristone) MEGACE ES (megestrol) Buprenorphine/Naloxone and VISTARIL (hydroxyzine pamoate) buprenorphine: ZUBSOLV (buprenorphine/naloxone) Suboxone  Detailed buprenorphine/naloxone and buprenorphine criteria found here

Non Preferred Criteria:  Bunavail is preferred over Zubsolv and other generic forms of buprenorphine/naloxone

Bunavail  History of Suboxone therapy within the past 6 months OR  History of Bunavail therapy within the past 3 months AND 55 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Hydroxyzine hcl 10mg tablets  6-12 years - Smart PA will automatically be issued for this age range

SUBLINGUAL ALLERGEN EXTRACT IMMUNOTHERAPY GRASTEK ORALAIR RAGWITEK SUBLINGUAL NITROGLYCERIN nitroglycerin lingual 12gm nitroglycerin lingual 4.9gm nitroglycerin sublingual NITROLINGUAL (nitroglycerin) 4.9gm NITROLINGUAL PUMPSPRAY (nitroglycerin) NITROMIST (nitroglycerin) 12gm NITROSTAT SUBLINGUAL (nitroglycerin) SmartPA MOVEMENT DISORDER AGENTS tetrabenazine Xenazine XENAZINE (tetrabenazine)  Documented diagnosis of Huntington’s Chorea MULTIPLE SCLEROSIS AGENTS SmartPA AUBAGIO (teriflunomide) AMPYRA (dalfampridine) All Agents AVONEX (interferon beta-1a) COPAXONE 40mg (glatiramer)  Documented diagnosis of multiple BETASERON (interferon beta-1b) EXTAVIA (interferon beta-1b) sclerosis COPAXONE 20mg (glatiramer) GLATOPA (glatiramer) Non Preferred Criteria GILENYA (fingolimod) PLEGRIDY (interferon beta-1a) 56 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Ampyra – MANUAL PA  18 years – minimum age limit AND  60 tablets/30 days (2 tablets/day) – quantity limit AND  Documented gait disorder associated with MS AND  NO seizure diagnosis or moderate to severe renal impairment AND  Initial authorization – requires a baseline Timed 25-foot Walk (T25FW) assessment and will be approved for 12 weeks OR  Additional prior authorizations - requires a benefit assessment measured by a 20% improvement in the T25FW from baseline. Renewal will not be approved if the 20% improvement is not maintained. A renewal will be issued in a 6 month intervals

NSAIDS SmartPA NON-SELECTIVE diclofenac EC ADVIL (ibuprofen) Non Preferred Criteria etodolac tab ANAPROX (naproxen)  Have tried 2 different preferred non- flurbiprofen CAMBIA (diclofenac) selective or NSAID/GI protectant CATAFLAM (diclofenac) ibuprofen combination agents in the past 6 DAYPRO (oxaprozin) months 57 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

58 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

 90 consecutive days on the requested agent in the past 105 days OR  Have tried 1 preferred COX-II Selective and 1 preferred Non- Selective Agent OR  Have tried 1 preferred COX-II Selective agent and a documented diagnosis of GI Bleed, GERD, PUD, GI Perforation, or Coagulation Disorder OPHTHALMIC ANTIBIOTICS bacitracin/neomycin/gramicidin AZASITE (azithromycin) bacitracin/polymyxin bacitracin CILOXAN Ointment (ciprofloxacin) BESIVANCE (besifloxacin) ciprofloxacin BLEPH-10 (sulfacetamide) erythromycin CILOXAN Solution (ciprofloxacin) gentamicin GARAMYCIN (gentamicin) levofloxacin gatifloxacin MOXEZA (moxifloxacin) NATACYN (natamycin) ofloxacin neomycin/bacitracin/polymyxin b polymyxin/trimethoprim NEO-POLYCIN (neomy/baci/polymyxin b) sulfacetamide NEOSPORIN (bacitracin/neomycin/gramicidin) tobramycin (oxy-tcn/polymyx sul) TOBREX (tobramycin) oint OCUFLOX (ofloxacin) VIGAMOX (moxifloxacin) POLYTRIM (polymyxin/trimethoprim) ZYMAR (gatifloxacin) 59 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

ANTIBIOTIC STEROID COMBINATIONS neomycin//polymyxin/dexamethasone BLEPHAMIDE (sulfacetamide/prednisolone) PRED-G (gentamicin/prednisolone) MAXITROL(neomycin/polymyxin/dexamethasone) sulfacetamide/prednisolone neomycin/bacitracin/polymyxin/hc TOBRADEX SUSPENSION/OINTMENT tobramycin/dexamethasone (tobramycin/dexamethasone) ZYLET (loteprednol/tobramycin)

OPHTHALMIC ANTI-INFLAMMATORIES SmartPA dexamethasone ACULAR LS (ketorolac) Non Preferred Criteria diclofenac ACUVAIL (ketorolac)  Have tried 2 different preferred agents FLAREX (fluorometholone) BROMDAY (bromfenac) in the past 6 months flurbiprofen bromfenac FML SOP (fluorometholone) DUREZOL (difluprednate) MAXIDEX (dexamethasone) FML FORTE (fluorometholone) prednisolone acetate ILEVRO (nepafenac) prednisolone NA phosphate LOTEMAX (loteprednol) VEXOL (rimexolone) NEVANAC (nepafenac) OCUFEN (flurbiprofen) PROLENSA (bromfenac) PRED MILD (prednisolone) PRED FORTE (prednisolone) VOLTAREN (diclofenac)

60 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

OPHTHALMICS, GLAUCOMA AGENTS SmartPA BETA BLOCKERS betaxolol BETAGAN (levobunolol) Non Preferred Criteria BETIMOL (timolol) BETOPTIC S (betaxolol)  Documented diagnosis of glaucoma carteolol OPTIPRANOLOL (metipranolol) AND ISTALOL (timolol) timolol gel  Have tried 2 different preferred agents in the past 6 months OR levobunolol TIMOPTIC (timolol)  90 consecutive days on the requested metipranolol agent in the past 105 days timolol solution CARBONIC ANHYDRASE INHIBITORS AZOPT (brinzolamide) dorzolamide TRUSOPT (dorzolamide) COMBINATION AGENTS 61 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

OTIC ANTIBIOTICS CIPRODEX (ciprofloxacin/dexamethasone) Age Edit CIPRO HC (ciprofloxacin/hydrocortisone) Age Edit Maximum Age Limit neomycin/polymyxin/hydrocortisone ciprofloxacin  8 years - Cipro HC ofloxacin COLY-MYCIN S (colistin/neomycin/ hydrocortisone)  14 years - Ciprodex CORTISPORIN-TC (colistin/neomycin/ hydrocortisone) DERMOTIC (fluocinolone)

62 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

PARATHYROID AGENTS calcitriol doxercalciferol ergocalciferol DRISDOL (ergocalciferol) ZEMPLAR (paricalcitol) HECTOROL (doxercalciferol) NATPARA (parathyroid hormone) paricalcitol ROCALTROL (calcitriol) SENSIPAR (cinacalcet)

PHOSPHATE BINDERS calcium acetate AURYXIA (ferric citrate) ELIPHOS (calcium acetate) FOSRENOL (lanthanum) PHOSLYRA (calcium acetate) PHOSLO (calcium acetate) RENAGEL (sevelamer HCl) RENVELA (sevelamer carbonate) sevelamer carbonate VELPHORO (sucroferric oxyhydronxide)

PLATELET AGGREGATION INHIBITORS SmartPA AGGRENOX (dipyridamole/aspirin) BRILINTA (ticagrelor) Zontivity – MANUAL PA cilostazol EFFIENT (prasugrel)  Documented diagnosis of myocardial clopidogrel PERSANTINE (dipyridamole) infarction or peripheral artery disease AND 63 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Non Preferred Criteria  Documented diagnosis AND  Have tried 2 different preferred agents in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days

Brilinta  Documented diagnosis for Acute Coronary Syndrome or Percutaneous Coronary Intervention OR  Therapy with Brilinta in the past 60 days

Effient  Documented diagnosis for Acute Coronary Syndrome or Percutaneous Coronary Intervention

PRENATAL VITAMINS CITRANATAL 90 DHA PACK B-NEXA Tablet Products not listed here are assumed to CITRANATAL ASSURE COMBO PACK CAVAN-EC SOD DHA VITAMINS be non-preferred. CITRANATAL B-CALM PACK COMPLETE NATAL DHA CITRANATAL DHA PACK COMPLETENATE Tablet CHEW CITRANATAL HARMONY Capsule CONCEPT OB Capsule CITRANATAL RX Tablet CORENATE-DHA COMBO PACK CONCEPT DHA Capsule DUET DHA BALANCED COMBO PACK FE C PLUS Tablet DUET DHA BALANCED COMBO PACK 64 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

‘Smart PA’ is Xerox’s proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not have electronic PA functionality. However, they must adhere to Medicaid’s PA criteria THERAPEUTIC PREFERRED AGENTS NON-PREFERRED AGENTS PA CRITERIA DRUG CLASS PRENATAL PLUS Tablet ED CYTE F Tablet SE-NATAL CHEWABLE Tablet FOLCAL DHA Capsule TARON-C DHA Capsule FOLCAPS OMEGA-3 Capsule TRICARE PRENATAL Tablet FOLIVANE-EC CALCIUM DHA COMBO VOL-PLUS Tablet FOLIVANE-OB Capsule VOL-TAB Rx FOLIVANE-PRX DHA NF Capsule GESTICARE DHA COMBO PACK ICAR-C PLUS SR Capsule ICAR-C PLUS Tablet NATAFORT Tablet NATELLE ONE Capsule NESTABS DHA COMBO PACK NESTABS PRENATAL Tablet NEXA SELECT Capsule PNV-DHA SOFTGEL PNV-SELECT Tablet PAIRE OB PLUS DHA COMBO PACK PR NATAL 400 COMBO PACK PR NATAL 430 COMBO PACK PR NATAL 430 EC COMBO PACK PREFERA OB Tablet PREFERA-OB ONE SOFTGEL PREFERA-OB PLUS DHA COMBO PACK PREFERA-OB PLUS DHA COMBO PACK PREFERA-OB Tablet PRENATABS FA Tablet PRENATAL 19 Tablet PRENATAL PLUS IRON Tablet PRENATAL VITAMINS Tablet PRENATE DHA SOFTGEL PRENATE ELITE Tablet PRENATE ESSENTIAL SOFTGEL PRENATE PLUS Tablet PRENAVITE Tablet PRENEXA Capsule 65 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Non Preferred Criteria  Have tried 1 preferred PAH agent in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days

66 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

PDE5’s sildenafil ADCIRCA (tadalafil) Non Preferred Criteria REVATIO (sildenafil)  Have tried 1 preferred PAH agent in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days

Revatio  < 1 year of age AND documented diagnosis of Pulmonary Hypertension, Patent Ductus Arteriosus, or Persistent Fetal Circulation OR 90 consecutive days on the requested agent in the past 105 days  > 18 years of age AND Non Preferred Criteria

Sildenafil 25mg, 50mg, or 100mg  < 12 years of age AND documented diagnosis of Pulmonary Hypertension, Patent Ductus Arteriosus, or Persistent Fetal Circulation OR history of heart transplant OR 90 consecutive days on the requested agent in the past 105 days

PROSTACYCLINS ORENITRAM ER (treprostinil) TYVASO (treprostinil) Non Preferred Criteria VENTAVIS (iloprost)  Have tried 1 preferred PAH agent in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days

67 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

SOLUABLE GUANYLATE CYCLASE STIMULATORS ADEMPAS (riociguat) Adempas  Have tried 1 preferred PAH agent in the past 6 months OR  90 consecutive days on the requested agent in the past 105 days OR  MANUAL PA for PAH WHO Group 4

SEDATIVE HYPNOTICS BENZODIAZEPINES estazolam DALMANE (flurazepam) Single source benzodiazepines and flurazepam DORAL (quazepam) barbiturates are NOT covered – NO temazepam (15mg and 30mg) HALCION (triazolam) PA’s will be issued for these drugs. RESTORIL (temazepam)

temazepam (7.5mg and 22.5mg) Quantity Limits – CUMULATIVE triazolam Quantity limit per rolling days for all strengths. SmartPA will allow an early refill override for one dose or therapy change per year.  31 units/31 days - all strengths

Triazolam – CUMULATIVE Quantity limit per rolling days for all strengths  10 units/31 days  60 units/365 days

SmartPA OTHERS zaleplon AMBIEN (zolpidem) Quantity Limits – CUMULATIVE zolpidem AMBIEN CR (zolpidem) Quantity limit per rolling days for all 68 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Non Preferred Criteria  Have tried 2 different preferred agents in the past 6 months

Hetlioz  Circadian rhythm sleep disorder AND  Diagnosis indicating total blindness of the patient

SELECT CONTRACEPTIVE PRODUCTS INJECTABLE CONTRACEPTIVES medroxyprogesterone acetate IM DEPO-PROVERA IM (medroxyprogesterone acetate) DEPO-SUBQ PROVERA 104 (medroxyprogesterone acetate) SmartPA ORAL CONTACEPTIVES ALL CONTRACEPTIVES ARE PREFERRED AMETHIA (levonorgestrel/ethinyl estradiol) Non Preferred Criteria EXCEPT FOR THOSE SPECIFICALLY AMETHYST (levonorgestrel/ethinyl estradiol)  1 claim with the requested agent in INDICATED AS NON-PREFERRED BEYAZ (ethinyl the past 105 days

69 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

70 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

SKELETAL MUSCLE RELAXANTS SmartPA baclofen AMRIX (cyclobenzaprine ER) Non Preferred Agents chlorzoxazone carisoprodol  Documented diagnosis for an cyclobenzaprine 5mg, 10mg carisoprodol compound approvable indication AND methocarbamol cyclobenzaprine 7.5mg, 15mg  Have tried 2 different preferred agents in the past 6 months tizanidine tablets cyclobenzaprine ER

dantrolene Carisoprodol FEXMID (cyclobenzaprine)  Documented diagnosis of acute LORZONE (chlorzoxazone) musculoskeletal condition AND metaxalone  NO history with meprobamate in the orphenadrine past 90 days AND orphenadrine compound  1 claim for cyclobenzaprine in the PARAFON FORTE DSC (chlorzoxazone) past 21 days OR a documented ROBAXIN (methocarbamol) intolerance to cyclobenzaprine AND SKELAXIN (metaxalone)  Quantity Limits SOMA (carisoprodol) o 18 tablets - to allow tapering off tizanidine capsules o 84 tablets/6 months ZANAFLEX (tizanidine)

SMOKING DETERRANTS NICOTINE TYPE nicotine gum NICODERM CQ PATCH nicotine lozenge NICORETTE LOZENGE nicotine patch NICORETTE GUM NICOTROL INHALER NICOTROL NASAL SPRAY

71 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

NON-NICOTINE TYPE bupropion ER ZYBAN (bupropion) Minimum Age Limit - Chantix CHANTIX (varenicline)  18 years

Quantity Limits  Chantix 0.5 mg, 1mg tablets and continuing pack – 336 tablets/year  Chantix Starter – 2 treatment courses/year

STEROIDS (Topical) SmartPA LOW POTENCY CAPEX (fluocinolone) alclometasone Non Preferred Criteria desonide DERMA-SMOOTHE-FS (fluocinolone)  Have tried 2 different preferred low hydrocortisone cr, oint, soln. DESONATE (desonide) potency agents in the past 6 months DESOWEN (desonide) fluocinolone oil hydrocortisone lotion PEDIACARE HC (hydrocortisone) PEDIADERM (hydrocortisone) VERDESO (desonide)

MEDIUM POTENCY fluocinolone CLODERM (clocortolone) Non Preferred Criteria hydrocortisone CUTIVATE (fluticasone)  Have tried 2 different preferred mometasone cr, oint. DERMATOP (prednicarbate) medium potency agents in the past 6 prednicarbate cr ELOCON (mometasone) months PANDEL (hydrocortisone probutate) fluticasone 72 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

HIGH POTENCY amcinonide cr, lot amcinonide oint Non Preferred Criteria betamethasone dipropionate cr, gel, lotion betameth diprop/prop gly cr, lot, oint  Have tried 2 different preferred high betamethasone valerate cr, lotion, oint. betamethasone dipropionate oint. potency agents in the past 6 months CAPEX (fluocinolone) BETA-VAL (betamethasone valerate) fluocinolone desoximetasone triamcinolone diflorasone DIPROLENE AF (betamethasone diprop/prop gly) ELOCON (mometasone) fluocinonide HALOG (halcinonide) KENALOG (triamcinolone) PEDIADERM TA (triamcinolone) TOPICORT (desoximetasone) TRIANEX (triamcinolone) VANOS (fluocinonide)

VERY HIGH POTENCY CLOBEX (clobetasol) clobetasol emollient Non Preferred Criteria TEMOVATE (clobetasol propionate) clobetasol propionate cr, foam, gel, oint, sol  Have tried 2 different preferred very ULTRAVATE (halobetasol) DIPROLENE (betamethasone diprop/prop gly) high potency agents in the past 6 halobetasol months 73 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

METHYLIN chewable tablets (methylphenidate) methylphenidate chewable Maximum Age Limit METHYLIN solution (methylphenidate) methylphenidate solution  21 years – diagnosis of ADD/ADHD ZENZEDI (dextroamphetamine) methylphenidate IR is required PROCENTRA (dextroamphetamine) Quantity Limits Applicable quantity limit per rolling days  62 tablets/ 31 days –Adderall, Desoxyn, Focalin, Methylin, Zenzedi  155 mL/ 31 days – Methylin solution, Procentra

Non-Preferred Criteria  Have tried 2 different preferred Short Acting agents in the past 6 months OR  1 claim for a 30 day supply with the requested agent in the past 180 days LONG-ACTING ADDERALL XR (amphetamine salt combination) amphetamine salt combination ER Minimum Age Limit DAYTRANA (methylphenidate) APTENSIO XR (methylphenidate)  6 years – Adderall XR, Aptensio XR, FOCALIN XR (dexmethylphenidate) CONCERTA (methylphenidate) Concerta, Daytrana, Dexedrine, 74 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Quantity Limits Applicable quantity limit per rolling days  31 tablets/ 31 days – Adderall XR, Aptensio XR, Concerta 18, 27, & 54 mg, Daytrana, Dexedrine Spansule, Focalin XR 5 & 10mg, Metadate CD, Methylin ER, Nuvigil 150 & 200 mg, Provigil 200mg, Ritalin LA & SR, Vyvanse  46.5 tablets/ 31 days – Provigil 100 mg  62 tablets/ 31 days – Concerta 36mg, Focalin XR 15 & 20mg, Nuvigil 50mg  372 mL/ 31 days – Quillivant XR

Provigil  Documented diagnosis of Narcolepsy, Obstructive Sleep Apnea, or Shift Work Disorder

Non-Preferred Criteria  Have tried 2 different preferred Long Acting agents in the past 6 months

75 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

Nuvigil  Documented diagnosis of Narcolepsy, Obstructive Sleep Apnea, or Shift Work Disorder AND  1 claim for a 30 day supply with the requested agent in the past 180 days OR  30 days of therapy with Provigil in the past 6 months AND 30 days of therapy in the past 6 months with a preferred stimulant that is indicated for the treatment of Narcolepsy, Obstructive Sleep Apnea, or Shift Work Disorder NON-STIMULANTS STRATTERA (atomoxetine) clonidine ER Minimum Age Limit guanfacine ER 6 years – Intuniv, Kapvay, Strattera INTUNIV (guanfacine ER) Maximum Age Limit KAPVAY (clonidine extended-release)  17 years – Intuniv, Kapvay

 21 years – diagnosis of ADD/ADHD is required

Quantity Limits Applicable quantity limit per rolling days  31 tablets/ 31 days – Intuniv, Strattera  124 tablets/ 31 days – Kapvay

Kapvay & Intuniv 76 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

TETRACYCLINES SmartPA doxycycline hyclate caps/tabs ACTICLATE (doxycyline)NR Non Preferred Agents doxycycline monohydrate caps (50mg & 100mg) ADOXA (doxycycline monohydrate)  Have tried 2 different preferred agents minocycline caps IR demeclocycline in the past 6 months tetracycline doxycycline monohydrate caps (75mg & 150mg) Demeclocycline doxycycline monohydrate tabs  Documented diagnosis of Diabetes DYNACIN (minocycline) Insipidus or SIADH will allow minocycline ER automatic approval. minocycline tabs ORACEA (doxycycline) SOLODYN (minocycline) VIBRAMYCIN cap/susp/syrup ULCERATIVE COLITIS and CROHN’S AGENTS *See Cytokine & CAM Antagonists Class for additional agents ORAL APRISO (mesalamine) ASACOL HD (mesalamine) Gender Limits ASACOL (mesalamine) AZULFIDINE (sulfasalazine)  Male - Giazo balsalazide AZULFIDINE ER (sulfasalazine) DIPENTUM (olsalazine) budesonide EC Non Preferred Criteria  Documented diagnosis for Ulcerative PENTASA 250mg (mesalamine) COLAZAL (balsalazide) Colitis AND sulfasalazine DELZICOL (mesalamine)  2 different preferred agents in the 77 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2016 UNIVERSAL PREFERRED DRUG LIST Version 2016.3f (For All Medicaid, MSCAN and CHIP Beneficiaries) Updated: 3/10/2016

78 This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. *Existing users will be grandfathered; grandfathering is defined as approving a non-preferred agent for an existing user; all other changes will not qualify for grandfathering To search the PDL, press CTRL + F